PaxMedica, Inc. (PXMD)

OTCMKTS · Delayed Price · Currency is USD
0.0005
+0.0001 (25.00%)
At close: Mar 4, 2026
400.00%
Market Cap 63.13K
Revenue (ttm) n/a
Net Income (ttm) -13.49M
Shares Out 126.26M
EPS (ttm) -1.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 996
Average Volume 58,557
Open 0.0006
Previous Close 0.0004
Day's Range 0.0005 - 0.0006
52-Week Range 0.0000 - 0.0200
Beta -38.20
RSI 53.25
Earnings Date Mar 13, 2026

About PaxMedica

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is dev... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol PXMD
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.